Emerging Research and News in Prostate Cancer Imaging — March 2025

EchoGo Amyloidosis, an echocardiography-based AI screening software, demonstrated a 93 percent AUROC for cardiac amyloidosis detection in a new multicenter study.

In a second part of a new podcast episode on recently published research on projected radiation-induced cancers from computed tomography (CT) scans, Mahadevappa Mahesh, MS, Ph.D., and Joseph Cavallo, M.D., offer current perspectives on cardiac CT dosing, AI advances and the importance of teamwork in ensuring appropriate dosing for CT.

For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.

In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.

The HCPCS level II code A9616 goes into effect on October 1 for the PSMA PET preparation kit, which received FDA approval in March.

For patients with amyloid β (Aβ)-positive findings on positron emission tomography, higher educational attainment was associated with accelerated accumulation and spread of tau, according to new research.